Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients

A pilot study

Jacopo Troisi, Claudia Cinque, Luigi Giugliano, Steven Symes, Sean Richards, Charles Adair, Pierpaolo Cavallo, Laura Sarno, Giovanni Scala, Maria Caiazza, Maurizio Guida

Research output: Contribution to journalArticle

Abstract

Background: Polycystic ovarian syndrome (PCOS) is a highly variable syndrome and one of the most common female endocrine disorders. Although the association inositols-glucomannan may represent a good therapeutic strategy in the treatment of PCOS women with insulin resistance, the effect of inositols on the metabolomic profile of these women has not been described yet. Results: Fifteen PCOS-patients and 15 controls were enrolled. Patients were treated with myo-inositol (1.75 g/day), D-chiro-inositol (0.25 g/day) and glucomannan (4 g/day) for 3 months. Blood concentrations of glucose, insulin, triglycerides and cholesterol, and ovary volumes and antral follicles count, as well as metabolomic profiles, were evaluated for control subjects and for cases before and after treatment. PCOS-patients had higher BMI compared with Controls, BMI decreased significantly after 3 months of treatment although it remained significantly higher compared to controls. 3-methyl-1-hydroxybutyl-thiamine-diphosphate, valine, phenylalanine, ketoisocapric, linoleic, lactic, glyceric, citric and palmitic acid, glucose, glutamine, creatinine, arginine, choline and tocopherol emerged as the most relevant metabolites for distinguishing cases from controls. Conclusion: Our pilot study has identified a complex network of serum molecules that appear to be correlated with PCOS, and with a combined treatment with inositols and glucomannan. Trial registration: ClinicalTial.gov, NCT03608813. Registered 1st August 2018 - Retrospectively registered,.

Original languageEnglish (US)
Article number25
JournalJournal of Ovarian Research
Volume12
Issue number1
DOIs
StatePublished - Mar 23 2019

Fingerprint

Metabolomics
Polycystic Ovary Syndrome
Inositol
Thiamine Pyrophosphate
Therapeutics
Tocopherols
Valine
Choline
Glutamine
Phenylalanine
Arginine
Insulin Resistance
Blood Glucose
Ovary
Creatinine
Milk
Triglycerides
Cholesterol
(1-6)-alpha-glucomannan
Insulin

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynecology

Cite this

Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients : A pilot study. / Troisi, Jacopo; Cinque, Claudia; Giugliano, Luigi; Symes, Steven; Richards, Sean; Adair, Charles; Cavallo, Pierpaolo; Sarno, Laura; Scala, Giovanni; Caiazza, Maria; Guida, Maurizio.

In: Journal of Ovarian Research, Vol. 12, No. 1, 25, 23.03.2019.

Research output: Contribution to journalArticle

Troisi, Jacopo ; Cinque, Claudia ; Giugliano, Luigi ; Symes, Steven ; Richards, Sean ; Adair, Charles ; Cavallo, Pierpaolo ; Sarno, Laura ; Scala, Giovanni ; Caiazza, Maria ; Guida, Maurizio. / Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients : A pilot study. In: Journal of Ovarian Research. 2019 ; Vol. 12, No. 1.
@article{86aba16a86d44d36bfab114f47e1fccb,
title = "Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: A pilot study",
abstract = "Background: Polycystic ovarian syndrome (PCOS) is a highly variable syndrome and one of the most common female endocrine disorders. Although the association inositols-glucomannan may represent a good therapeutic strategy in the treatment of PCOS women with insulin resistance, the effect of inositols on the metabolomic profile of these women has not been described yet. Results: Fifteen PCOS-patients and 15 controls were enrolled. Patients were treated with myo-inositol (1.75 g/day), D-chiro-inositol (0.25 g/day) and glucomannan (4 g/day) for 3 months. Blood concentrations of glucose, insulin, triglycerides and cholesterol, and ovary volumes and antral follicles count, as well as metabolomic profiles, were evaluated for control subjects and for cases before and after treatment. PCOS-patients had higher BMI compared with Controls, BMI decreased significantly after 3 months of treatment although it remained significantly higher compared to controls. 3-methyl-1-hydroxybutyl-thiamine-diphosphate, valine, phenylalanine, ketoisocapric, linoleic, lactic, glyceric, citric and palmitic acid, glucose, glutamine, creatinine, arginine, choline and tocopherol emerged as the most relevant metabolites for distinguishing cases from controls. Conclusion: Our pilot study has identified a complex network of serum molecules that appear to be correlated with PCOS, and with a combined treatment with inositols and glucomannan. Trial registration: ClinicalTial.gov, NCT03608813. Registered 1st August 2018 - Retrospectively registered,.",
author = "Jacopo Troisi and Claudia Cinque and Luigi Giugliano and Steven Symes and Sean Richards and Charles Adair and Pierpaolo Cavallo and Laura Sarno and Giovanni Scala and Maria Caiazza and Maurizio Guida",
year = "2019",
month = "3",
day = "23",
doi = "10.1186/s13048-019-0500-x",
language = "English (US)",
volume = "12",
journal = "Journal of Ovarian Research",
issn = "1757-2215",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients

T2 - A pilot study

AU - Troisi, Jacopo

AU - Cinque, Claudia

AU - Giugliano, Luigi

AU - Symes, Steven

AU - Richards, Sean

AU - Adair, Charles

AU - Cavallo, Pierpaolo

AU - Sarno, Laura

AU - Scala, Giovanni

AU - Caiazza, Maria

AU - Guida, Maurizio

PY - 2019/3/23

Y1 - 2019/3/23

N2 - Background: Polycystic ovarian syndrome (PCOS) is a highly variable syndrome and one of the most common female endocrine disorders. Although the association inositols-glucomannan may represent a good therapeutic strategy in the treatment of PCOS women with insulin resistance, the effect of inositols on the metabolomic profile of these women has not been described yet. Results: Fifteen PCOS-patients and 15 controls were enrolled. Patients were treated with myo-inositol (1.75 g/day), D-chiro-inositol (0.25 g/day) and glucomannan (4 g/day) for 3 months. Blood concentrations of glucose, insulin, triglycerides and cholesterol, and ovary volumes and antral follicles count, as well as metabolomic profiles, were evaluated for control subjects and for cases before and after treatment. PCOS-patients had higher BMI compared with Controls, BMI decreased significantly after 3 months of treatment although it remained significantly higher compared to controls. 3-methyl-1-hydroxybutyl-thiamine-diphosphate, valine, phenylalanine, ketoisocapric, linoleic, lactic, glyceric, citric and palmitic acid, glucose, glutamine, creatinine, arginine, choline and tocopherol emerged as the most relevant metabolites for distinguishing cases from controls. Conclusion: Our pilot study has identified a complex network of serum molecules that appear to be correlated with PCOS, and with a combined treatment with inositols and glucomannan. Trial registration: ClinicalTial.gov, NCT03608813. Registered 1st August 2018 - Retrospectively registered,.

AB - Background: Polycystic ovarian syndrome (PCOS) is a highly variable syndrome and one of the most common female endocrine disorders. Although the association inositols-glucomannan may represent a good therapeutic strategy in the treatment of PCOS women with insulin resistance, the effect of inositols on the metabolomic profile of these women has not been described yet. Results: Fifteen PCOS-patients and 15 controls were enrolled. Patients were treated with myo-inositol (1.75 g/day), D-chiro-inositol (0.25 g/day) and glucomannan (4 g/day) for 3 months. Blood concentrations of glucose, insulin, triglycerides and cholesterol, and ovary volumes and antral follicles count, as well as metabolomic profiles, were evaluated for control subjects and for cases before and after treatment. PCOS-patients had higher BMI compared with Controls, BMI decreased significantly after 3 months of treatment although it remained significantly higher compared to controls. 3-methyl-1-hydroxybutyl-thiamine-diphosphate, valine, phenylalanine, ketoisocapric, linoleic, lactic, glyceric, citric and palmitic acid, glucose, glutamine, creatinine, arginine, choline and tocopherol emerged as the most relevant metabolites for distinguishing cases from controls. Conclusion: Our pilot study has identified a complex network of serum molecules that appear to be correlated with PCOS, and with a combined treatment with inositols and glucomannan. Trial registration: ClinicalTial.gov, NCT03608813. Registered 1st August 2018 - Retrospectively registered,.

UR - http://www.scopus.com/inward/record.url?scp=85063413298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063413298&partnerID=8YFLogxK

U2 - 10.1186/s13048-019-0500-x

DO - 10.1186/s13048-019-0500-x

M3 - Article

VL - 12

JO - Journal of Ovarian Research

JF - Journal of Ovarian Research

SN - 1757-2215

IS - 1

M1 - 25

ER -